Peptides for weight loss: GLP-1 research molecules
Modern GLP-1 molecules investigated in global studies of metabolic health.
Peptides for weight loss is the common name for incretin molecules studied in metabolic research as agonists of the GLP-1, GIP and glucagon receptors. They include Retatrutide, Tirzepatide, Cagrilintide and Mazdutide. At Molequa® these are strictly reference substances for laboratory research with HPLC purity of at least 99 % and a certificate of analysis for every batch, not medicines.
- −25% pre-order
Metabolism5-Amino-1MQ
4.9 (20)Fat burning, NAD+ research
- ≥ 99 % declared, CoA with first batch Test results
- EU stock
€53.90 €40.43 - −25% pre-order
MetabolismAOD-9604
5.0 (40)Fat burning peptide research
- ≥ 99 % Test results
- EU stock
€35.90 €26.93 - −25% pre-order
MetabolismCagrilintide
4.9 (61)Appetite control research
- ≥ 99 % declared, CoA with first batch Test results
- EU stock
€80.90 €60.68 - −25% pre-order
MetabolismMazdutide
5.0 (24)GLP-1/glucagon research
- ≥ 99 % declared, CoA with first batch Test results
- EU stock
€107.90 €80.93 - −25% pre-order
MetabolismRetatrutide
4.8 (74)Triple agonist obesity research
- ≥ 99 % Test results
- EU stock
€107.90 €80.93 - −25% pre-order
MetabolismSurvodutide
4.7 (35)Dual GLP-1/glucagon agonist
- ≥ 99 % Test results
- EU stock
€116.90 €87.68 - −25% pre-order
MetabolismTesofensine
4.8 (18)Monoamine reuptake inhibitor, metabolic research
- ≥ 99 % Test results
- EU stock
€62.90 €47.18
Research context
GLP-1 and dual or triple incretin-receptor agonists represent the most active field of metabolic peptide research today. Molecules such as retatrutide, cagrilintide and mazdutide are investigated in large clinical programmes for their effects on glucose homeostasis and energy balance; retatrutide reported roughly 24 % mean body-weight reduction in a Phase 2 trial (Jastreboff et al., NEJM 2023). These peptides are supplied strictly as reference material for laboratory research.
FAQ
Which peptides are most studied for weight loss?
Incretin molecules have the most publications: Tirzepatide (GIP and GLP-1) and Retatrutide (GIP, GLP-1 and glucagon). In a phase 2 trial Retatrutide reached a mean weight reduction of 24.2 % after 48 weeks (Jastreboff 2023, NEJM, n = 338). Cagrilintide is studied as an amylin analogue.
What is the difference between Retatrutide and Tirzepatide?
The number of activated receptors. Tirzepatide acts on two (GIP and GLP-1), Retatrutide on three (GIP, GLP-1 and glucagon). The glucagon arm is what sets Retatrutide apart in the research context.
Are these peptides the same as Mounjaro or Wegovy?
No. Mounjaro and Wegovy are registered prescription medicines. Our products are reference substances for laboratory research (RUO); they are not medicines and are not intended for human or animal consumption.
How do I verify quality before buying?
The batch-specific certificate of analysis is available on the product page before you order. It lists HPLC purity (≥ 99 %), identity confirmation by mass spectrometry, the lot number and the analysis date. Testing is performed by the independent laboratory Janoshik Analytical.
